Welcome to BioSeeker Group!

Triple Analysis: Apoptosis, Antibodies and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4991
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Apoptosis, Antibodies and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies by the mechanism/target/effect of Apoptosis and by the two compound strategies of Antibodies and Peptides.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Apoptosis, Antibodies and Peptides.

    To find out more about Triple Analysis: Apoptosis, Antibodies and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Apoptosis, Antibodies and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies by the mechanism/target/effect of Apoptosis and by the two compound strategies of Antibodies and Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part II: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

Part II: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
10 Disclaimer 2361
Figures: Includes 7 Figures
Tables: Includes 355 Tables
Total Number of Pages: 2,361

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
7TM Pharma
A&G Pharmaceutical
Abbott
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adherex
Advanced Life Sciences
AEgera
AEterna Zentaris
Affibody
Affimed Therapeutics
Affitech
Affymax
Agenus
AGY Therapeutics
Aida Pharmaceuticals
Aileron Therapeutics
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Algeta
Allostera
Allosterix
Alnylam
ALSP
Altor BioScience
Ambrilia Biopharma
Amgen
Amorfix Life Sciences
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
Antisoma
Aphios
AplaGen Biopharmaceuticals
Apogenix
ApopLogic Pharmaceuticals
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Ardana
Areva
arGEN-X
Arno Therapeutics
ArQule
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
Avila Therapeutics
Basilea Pharmaceutica
Baxter International
Bayer
Berkeley Lab
BioAlliance Pharma
BioAxone
Biocad
Biocon
Biogen Idec
BioInvent
Biokine Therapeutics
Biolex
BioLineRx
Biomas
Bionovo
Biosceptre
Biotecnol
Biotest
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celecure
Celera
Celldex Therapeutics
Celltrion
Celtic Pharma
Center of Molecular Immunology
Centrose
Cephalon
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
Chiasma
Chlorogen
Chroma Therapeutics
Circadian Technologies
Cleveland BioLabs
Clinuvel
CombinatoRx
Compugen
Coronado Biosciences
Critical Outcome Technologies
CSL
CuraGen
Curaxis
CureTech
Curis
Customized Therapeutics
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Dendreon
DeveloGen
DiaMedica
Digna Biotech
Dompe
Dongkook Pharm
Dr Reddy’s
Dyax
Eisai
Elan
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
EpiCept
Ergon Pharmaceuticals
Erimos
Esperance Pharmaceuticals
EUSA Pharma
Exelixis
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
Favrille
Femta Pharmaceuticals
FibroGen
Five Prime Therapeutics
Formula Pharmaceuticals
Fusion Antibodies
Galaxy Biotech
Galena Biopharma
GammaCan
Ganymed Pharmaceuticals
Gene Techno Science
Genencor
Genentech
Generex
Genmab
Genomic Systems
GENova Biotherapeutics
Genovax
GenPat77
Genta
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
Glycotope
GP Pharm
GPC Biotech
Green Cross
Gryphon Therapeutics
Harbor BioSciences
Hawthorn Pharmaceuticals
Hoffmann-La Roche
Human Genome Sciences
Idera Pharmaceuticals
IDM Pharma
ImClone Systems
IMED
Immune Pharmaceuticals
ImmunoCellular Therapeutics
ImmunoGen
Immunomedics
Immunotope
ImmuPharma
Immutep
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intracel
Intradigm
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Johnson & Johnson
KAEL-GemVax
Kaketsuken
KaloBios
Kalypsys
Karyon-CTT
Keryx Biopharmaceuticals
Kirax
Kirin Pharma
Kissei
Kyowa Hakko Kirin
Kyto Biopharma
Lee’s Pharmaceutical
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
MAT Biopharma
MBiotec
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
MethylGene
Micromet
Mitsubishi Tanabe Pharma
MolMed
Mycenax
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neuren
Neurobiological Technologies
Nidus Laboratories
NIH
Nippon Shinyaku
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
Novelix
Novogen
NPS Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Onyvax
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
Panacea
PanaGin
PanGenetics
Patrys
Pepscan Therapeutics
Peptagen
PepTx
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
Pierre Fabre
Prima Biomed
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progenics Pharmaceuticals
ProMetic Life Sciences
Protagonist
Q Chip
QLT
Ramot
Raptor Pharmaceutical
Reata Pharmaceuticals
Recepta biopharma
Receptor BioLogix
Regeneron
Regulon
Rigel
Rosetta Genomics
Sanofi
Santaris Pharma
Sarepta Therapeutics
SBI Biotech
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Senesco Technologies
Serometrix
Shanghai CP Guojian
Shenogen
Shire
Sigma-Tau
Soligenix
Spectrum Pharmaceuticals
SRI International
Stainwei Biotech
Sunol Molecular
SuperGen
SuppreMol
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Symphogen
Synageva BioPharma
SynerGene Therapeutics
Tactic Pharma
Takeda
Tamir Biotechnology
Targa Therapeutics
Taxolog
TeGenero
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
Tolerx
TopoTarget
Tracon Pharmaceuticals
Transgene
Trillium Therapeutics
Trion Pharma
UCB
UMN Pharma
Unigene
United Biomedical
United Therapeutics
Vaccinex
Wakunaga
ValiRx
VasGene Therapeutics
Vaxil BioTherapeutics
Vaxon Biotech
VBL Therapeutics
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
Wilex
VioQuest
Viragen
Viralytics
ViroTarg
Viventia Biotech
VM Discovery
XBiotech
Xencor
Xerion
Xigen
Xoma
Y’s Therapeutics
YM BioSciences
Zelos Therapeutics
Zenotech
Zensun
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abagovomab
abarelix
ABT-510
adecatumumab
AEG-35156
AEZS-108
afamelanotide
aflibercept
AGS-1C4D4
ALD-518
alemtuzumab
alvocidib
amatuximab
AME-133
AMG-386
angiopep+paclitaxel
APG-101
ARQ-197
AS-101
AS-1411
AV-299
bardoxolone methyl
belimumab
belinostat
bevacizumab
BHQ880
blinatumomab
BMS-663513
BMS-936558
bortezomib
bosutinib
brentuximab vedotin
BT-062
BZL-101
canfosfamide hydrochloride
carlumab
catumaxomab
CBP-501
CDX-1307
CDX-1401
cenersen
cetuximab
cintredekin besudotox
cixutumumab
CMAB302
CMAB304
conatumumab
corticorelin acetate
crolibulin
CT-011
dalotuzumab
daratumumab
denosumab
deslorelin
dinaciclib
dulanermin
E-75
elotuzumab
EMD-273063
EMD525797
emepepimut-S
enzastaurin hydrochloride
EP-100
epratuzumab
epratuzumab-Y90
ertumaxomab
farletuzumab
figitumumab
fosbretabulin tromethamine
FPI-01
fresolimumab
galiximab
ganitumab
gataparsen
gemtuzumab ozogamicin
girentuximab
glembatumumab vedotin
goserelin
GS-6634
GT-111
GV-1001
GX-301
HE-3235
Her-2/Neu peptides
histrelin
I-131-labetuzumab
ibritumomab tiuxetan
icrucumab
idronoxil
imatinib mesilate
imetelstat
imMucin
inotuzumab ozogamicin
intetumumab
IPH-2102
ipilimumab
IPP-204106
iratumumab
ISA-P53-01
kahalalide F
L19-TNFalpha
lanreotide
lestaurtinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
lintuzumab
LIP-131I
litronesib
lonaprisan
lorvotuzumab mertansine
lucatumumab
lumiliximab
LY2495655
lymphomun
MABp1
mapatumumab
MCS-110
MDX-1379
MEDI-551
MEDI-573
milatuzumab
milatuzumab-doxorubicin
MKC-1
MM-111
MM-121
mocetinostat
mogamulizumab
MOR202
MOR208
MORAb-004
motexafin gadolinium
moxetumomab pasudotox
NAFB001
naptumomab estafenatox
natalizumab
navitoclax
necitumumab
netupitant
nimotuzumab
noscapine
obinutuzumab
oblimersen sodium
octreotide
octreotide, LAR
ofatumumab
olaratumab
ON-01910
onartuzumab
Oncohist
Onyvax-105
oregovomab
OTS-102
ozarelix
panitumumab
panobinostat
pasireotide
pasireotide LAR
PAT-SC1
PBI-1402
PCI-24781
pertuzumab
PF-4856884
plitidepsin
polyclonal antibody stimulator
PX-12
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
ramucirumab
Reditux
retaspimycin
RG-7160
rilotumumab
rindopepimut
rituximab
robatumumab
romiplostim
romurtide
sagopilone
samalizumab
SAR-3419
seliciclib
siltuximab
sotatercept
SPC-2996
ß-lapachone
SU-6668
Survivac
Sym-004
Tenarad
terameprocol
thymalfasin
tigapotide triflutate
tigatuzumab
tipifarnib
TL-32711
TM-30339
tocilizumab
TRC-105
tremelimumab
triciribine phosphate
TRU-016
tucotuzumab celmoleukin
U3-1287
Ublituximab
vapreotide, immediate-release
veltuzumab
vitespen
volasertib
volociximab
vosaroxin
VX-001
XL-147
XL-647
yttrium Y 90 clivatuzumab tetraxetan
zalutumumab
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Apoptosis, Antibodies and Peptides.
    To find out more about Triple Analysis: Apoptosis, Antibodies and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Apoptosis, Antibodies and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Learn More


Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer
This triple analysis focuses on cancer drug development strategies in Leukemia, Lymphoma and Pancreatic Cancer. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Learn More


Wnt Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 228 companies plus partners who are today developing 253 Wnt pathway targeting drugs in 935 developmental projects in cancer across 204 different targets. In addition, there are 2 suspended drugs and another 118 drugs where development has been ceased. Learn More